Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | CSK | P41240 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14785716 | 0.87 | POLB (0.41) | GAASMN1; SMN2ALOX15DRD2DRD4 | |
| SCHEMBL1695151 | 0.84 | KDM4E (0.47) | ALOX15DRD2DRD4DRD3POLB | |
| SCHEMBL1695184 | 0.84 | ALDH1A1 (0.44) | GAASMN1; SMN2ALOX15DRD2DRD4 | |
| SCHEMBL13135665 | 0.82 | ALOX15 (0.51) | GAASMN1; SMN2ALOX15DRD2DRD4 | |
| SCHEMBL1695102 | 0.82 | KDM4E (0.50) | POLBCYP1A2MAPK1CYP2C19KDM4E | |
| SCHEMBL17045671 | 0.80 | SMN1; SMN2 (0.51) | GAASMN1; SMN2ALOX15DRD4NUDT14 | |
| SCHEMBL11688080 | 0.79 | MAPK1 (0.41) | GAASMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL1694604 | 0.79 | KCNJ6 (0.39) | GAASMN1; SMN2POLBCYP1A2MAPK1 | |
| SCHEMBL25793180 | 0.79 | GAA (0.50) | GAASMN1; SMN2ALOX15KDM4ENUDT14 | |
| SCHEMBL18161146 | 0.77 | ALOX15 (0.43) | GAASMN1; SMN2ALOX15DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2755962-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8637509-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2566479-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343056-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | GAA 1711/4885SMN1; SMN2 2914/4885ALOX15 2644/4885 |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | GAA 2757/4885SMN1; SMN2 1963/4885ALOX15 844/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | GAA 1711/4885SMN1; SMN2 2914/4885ALOX15 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.